Lotus Clinical Research is a CRO and research site specializing in analgesic studies -- a leading contract research organization (CRO), delivering comprehensive Phase I-IV solutions and results to clients since its inception in 2001. Lotus specializes in the study of medications and devices used for analgesia, drug delivery methods for which pain or pain relief is to be measured, and the side effects of analgesic treatments.
Since 2001, Lotus has honed its study design and conduct methodology, interacts on behalf of clients with the FDA’s Analgesics Division, and has a unique understanding of how to efficiently navigate the agency’s regulatory framework. Lotus has developed a proprietary placebo response toolkit for patient education and staff training, which are designed to maximize assay sensitivity, thus increasing effect size by minimizing variability and placebo response in analgesic clinical trials. Lotus’ staff are trained to understand the primary endpoint of each investigation and its method of calculation, so they can focus their efforts on obtaining nonbiased and accurate data. As a scientifically driven CRO whose expertise has been adapted to fit the needs of complex and nuanced analgesic investigations, Lotus provides sponsors with efficient project management and program-wide scientific support to increase the probability of positive clinical trial outcomes. For more information, visit www.lotuscr.com.
Led by Dr. Neil Singla, an internationally recognized key opinion leader in analgesic methodology, with extensive experience in analgesic protocol design, Lotus specializes in Acute Pain, Chronic Pain, Analgesic Phase 1/Proof-of-Concept, and Opioid-Induced Constipation studies.
Lotus CRO services include industry leaders and specialists, providing clients with the following solutions:
Our clients are typically pharmaceutical or device companies with analgesic products they would like to bring to market as quickly as possible. Utilizing Lotus’ proprietary expertise to minimize variability, reduce placebo response, and increase effect size, clients can enhance the probability of positive clinical trial outcomes.